NM_007294.4:c.5096G>A

Variant summary

Our verdict is Pathogenic.
>+14 Pathogenic
-7
-6
-1
0
+5
+6
+9
+10
B
LB
VUS
LP
P
The variant received 21 classification points (ACMG Germline Pathogenicity v2019). PS3PS4_SupportingPM1PM2_SupportingPM5PP1PP3_ModeratePP5_Very_Strong

The NM_007294.4(BRCA1):c.5096G>A (p.Arg1699Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a cumulative frequency of 0.0000186 (AC=30) in the gnomAD database across 1,613,816 control chromosomes (no homozygotes observed). The grpmax filtering allele frequency (95% CI) is 0.00002. In-silico predictor (REVEL) classifies this variant as likely damaging/oncogenic. Splicing prediction tools (SpliceAI) predict no significant impact on normal splicing. Variant has been reported in ClinVar as Pathogenic/Likely Pathogenic (★★★). ClinVar reports functional evidence for this variant: "SCV000043748: (2011) found that expression of human BRCA1 with the R1699Q substitution reduced embryonic stem cell survival and caused upregulation of microRNA-155 (MIR155" and additional evidence is available in ClinVar. A different missense at the same amino acid position has been reported as Pathogenic/Likely Pathogenic in ClinVar: p.R1699L: Likely_pathogenic (ClinVar VariationId 55398, 2 stars) Other variants at the same amino acid position have been reported in ClinVar (not pathogenic): p.R1699= (synonymous): Likely_benign (ClinVar VariationId 1745302, 1 star); p.R1699= (synonymous): Likely_benign (ClinVar VariationId 873409, 2 stars); p.R1699P: Uncertain_significance (ClinVar VariationId 55397, 3 stars); p.R1699G: unknown significance (ClinVar VariationId 869021); p.R1699= (synonymous): Likely_benign (ClinVar VariationId 55395, 3 stars) This exact variant is established as oncogenic in: CGI (Cancer Genome Interpreter). This exact variant is curated in the UniProt human variants database as Uncertain Significance, associated with Breast-ovarian cancer, familial, susceptibility to, 1 (brovca1); it is also listed as a COSMIC curated somatic variant.

Frequency

Genomes: 𝑓 0.000013 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000019 ( 0 hom. )

Consequence

BRCA1
NM_007294.4 missense

Predictors

13
5
1
REVEL: 0.79 : Pathogenic

Clinical Significance

Pathogenic reviewed by expert panel P:55U:2O:1

Conservation

PhyloP100: 4.86

Publications

107 publications found
Genes affected
BRCA1 (HGNC:1100): (BRCA1 DNA repair associated) This gene encodes a 190 kD nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The BRCA1 gene contains 22 exons spanning about 110 kb of DNA. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2020]
BRCA1 Gene-Disease associations (from GenCC):
  • BRCA1-related cancer predisposition
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
  • breast-ovarian cancer, familial, susceptibility to, 1
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, Ambry Genetics, Labcorp Genetics (formerly Invitae)
  • Fanconi anemia, complementation group S
    Inheritance: AR Classification: DEFINITIVE, STRONG, MODERATE, LIMITED Submitted by: Ambry Genetics, G2P, Labcorp Genetics (formerly Invitae), ClinGen
  • pancreatic cancer, susceptibility to, 4
    Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
  • hereditary breast ovarian cancer syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • Fanconi anemia
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

new If you want to explore the variant's impact on the transcript NM_007294.4, check out the Mutation Effect Viewer. This is especially useful for frameshift variants or if you want to visualize the effect of exon loss / intron retention.

Classification according to ACMG Germline Pathogenicity v2019

Classification was made for transcript:

Our verdict: Pathogenic. The variant received 21 points.

PS3Functional studies show damaging effect
Well-established functional study supports damaging effect (PS3); SCV000043748: (2011) found that expression of human BRCA1 with the R1699Q substitution reduced embryonic stem cell survival and caused upregulation of microRNA-155 (MIR155; 609337), which has a role in promoting cell growth and is upregulated in various human cancers. Wildtype BRCA1, but not BRCA1 with the R1699Q substitution, downregulated mouse Mir155 expression by recruiting Hdac2 (605164) to the Mir155 promoter, resulting in deacetylation of histones H2a (see 142720) and H3 (see 601128).; SCV000076803: While the results are somewhat conflicting among the different reports, experimental studies have shown that this missense change can disrupt several functional activities of the BRCA1 protein, including transactivation (PMID: 18036263, 17308087, 11157798), phosphopeptide binding (PMID: 21473589, 15133503, 15133502), and nuclear foci formation (PMID: 18036263). RNA analysis performed to evaluate the impact of this missense change on mRNA splicing indicates it does not significantly alter splicing (internal data).; SCV000186568: In one functional study, the p.R1699Q alteration was shown to destabilize the BRCT domain of the BRCA1 protein and demonstrated reduced, but not abolished, BRCA1 activity (Lovelock PK et al. Breast Cancer Res. 2007;9:R82). In another functional study analyzing protein expression levels in transfected mouse embryonic stem cells, the p.R1699Q alteration showed an intermediate effect in a cisplatin sensitivity assay and a deleterious effect in a PARP inhibitor assay.; SCV000683252: Functional studies have reported that this variant impairs BRCA1 function in transcription activation, cisplatin and PARP inhibitor sensitivity, and homology-directed DNA repair assays (PMID: 11157798, 30458859, 30765603, 32546644).; SCV000693499: Experimental studies have shown that this missense change can disrupt several functional activities of the BRCA1 protein, including transactivation (PMID: 18036263, 17308087, 11157798), phosphopeptide binding (PMID: 21473589, 15133503, 15133502), and nuclear foci formation (PMID: 18036263).; (+9 more)
PS4Prevalence increased in affected individuals
Rare variant reported in affected individuals by ≥2 independent ClinVar submitters (PS4_Supporting); 17 ClinVar submitter(s) report the variant in affected individuals; SCV000043748: In a Scandinavian family (LUND488) segregating breast-ovarian cancer (604370), Vallon-Christersson et al.; SCV000076803: This variant has been reported in individuals and families affected with breast and/or ovarian cancer (PMID: 11504767, 12827452, 16683254, 20455026, 24504028, 24728189, 25452441, 28490613). In a large family cohort study, including 67 families in which the probands carried the Arg1699Gln change, this variant was shown to segregate with breast and ovarian cancer (PMID: 22889855).; SCV000186568: This mutation has also been detected in trans with BRCA1 c.181T>G (p.C61G) in an individual diagnosed with breast cancer at age 30 years and a mild Fanconi anemia phenotype lacking chromosome fragility (Keupp K et al. Mol Genet Genomic Med 2019 09;7(9):e863).; SCV000605739: The p.Arg1699Gln variant in BRCA1 has been reported in >60 individuals with BRCA1-associated cancers and segregated with disease in multiple relatives from 30 families (Spurdle 2012, Shimelis 2017, Moghadasi 2018). This variant has been described as having reduced penetrance compared to other disease-causing variants: up to 24% risk of BRCA1-related cancer by age 70 (95% CI, 10% to 40%) for Arg1699Gln carriers vs. 58% (95% CI, 7% to 72%) for Arg1699Trp carriers vs. 4.6% risk for women in the general population (Spurdle 2012, Moghadasi 2018).; SCV000683252: This variant has been detected in over 20 individuals and families affected with breast and ovarian cancer (PMID: 11157798, 11410501, 11504767, 12827452, 24504028, 24728189, 25452441, 27495310, 28283652, 29486991, 30287823, 33471991, 35039564, 37563628). This variant has been reported to have reduced penetrance, conferring intermediate risk for breast and ovarian cancer based on case-control studies, carrier family history, segregation and functional studies (PMID: 16489001, 22889855, 28283652, 28490613, 39488595).; (+13 more)
PM1Mutational hot spot or critical domain
Missense neighbourhood hotspot (≥2 P/LP within ±8 AA, OR ≥ 5 vs. background) — PM1; In-domain: 0 pathogenic, 0 benign rare missense variants; ±8 AA neighbourhood: 31 pathogenic, 8 benign (OR vs. background: 18.5)
PM2Absent/extremely low in population databases
Rare in gnomAD for AD/XL gene (popmax AF below threshold) — PM2 Supporting; GnomAD popmax AF = 0.00002 — borderline rare for AD+AR gene (base 0.0001, raised to 0.000118 by highest known P/LP ClinVar AF 0.000118) — PM2 supporting
PM5Novel missense at known pathogenic residue
Different pathogenic missense at same AA residue in ClinVar (PM5); ClinVar contains a germline Pathogenic/Likely Pathogenic entry at the same amino acid position with a different amino acid change: p.R1699L: Likely_pathogenic (ClinVar VariationId 55398, 2 stars); Other variants at the same amino acid residue (not pathogenic): p.R1699= (synonymous): Likely_benign (ClinVar VariationId 1745302, 1 star); p.R1699= (synonymous): Likely_benign (ClinVar VariationId 873409, 2 stars); p.R1699P: Uncertain_significance (ClinVar VariationId 55397, 3 stars); p.R1699G: unknown significance (ClinVar VariationId 869021); p.R1699= (synonymous): Likely_benign (ClinVar VariationId 55395, 3 stars)
PP1Cosegregation with disease
ClinVar submission reports cosegregation with disease (PP1); SCV000043748: In a Scandinavian family (LUND488) segregating breast-ovarian cancer (604370), Vallon-Christersson et al.; SCV000076803: In a large family cohort study, including 67 families in which the probands carried the Arg1699Gln change, this variant was shown to segregate with breast and ovarian cancer (PMID: 22889855). It has also been observed to segregate with disease in related individuals.; SCV000186568: In a study comparing phenotype and segregation data from 68 p.R1699Q families to 34 pathogenic BRCA1 p.R1699W kindreds and 243 BRCA1 mutation-free families, results strongly supported p.R1699Q as an intermediate risk allele, conferring an estimated 24% (95% CI: 10-40%) risk of female breast or ovarian cancer by age 70 (Spurdle AB et al. J. Med. Genet. 2012 Aug;49:525-32).; SCV000605739: The p.Arg1699Gln variant in BRCA1 has been reported in >60 individuals with BRCA1-associated cancers and segregated with disease in multiple relatives from 30 families (Spurdle 2012, Shimelis 2017, Moghadasi 2018).; SCV000683252: This variant has been reported to have reduced penetrance, conferring intermediate risk for breast and ovarian cancer based on case-control studies, carrier family history, segregation and functional studies (PMID: 16489001, 22889855, 28283652, 28490613, 39488595). A study of 129 families carrying this variant have shown cumulative risks for this variant by age 70 years are about 20% (95% CI 13% to 32%) for breast cancer and 6% (95% CI 3% to 25%) for ovarian cancer, which are between that for BRCA1 truncating variants and the general population (PMID: 28490613).; (+4 more)
PP3Computational evidence supports damaging effect
Germline meta computational scorer (REVEL/MetaRNN/BayesDel) predicts damaging effect — moderate evidence (PP3); Splicing verdict: not pathogenic; Germline computational verdict: pathogenic (Moderate)
PP5Reputable source reports pathogenic
ClinVar ≥3 stars pathogenic — very strong (PP5); ClinVar submissions overwhelmingly pathogenic (≥10 total, ≥80% P/LP, <10% B/LB) — strong (PP5, count-based); ClinVar germline classification: Pathogenic/Likely Pathogenic, 3 star(s). ClinVar submissions strongly and reliably favor pathogenicity (51/53 total P/LP)

Variant Effect in Transcripts

Automated classification analysis was done for transcript: NM_007294.4. You can select a different transcript below to see updated classification assignments.

RefSeq Transcripts

BRCA1 NM_007294.4
MANE Select
HGVSc / HGVSpc.5096G>Ap.Arg1699Gln
Exon rankExon 17 of 23
missense
Prot: NP_009225.1
BRCA1 NM_001407581.1
HGVSc / HGVSpc.5162G>Ap.Arg1721Gln
Exon rankExon 18 of 24
missense
Prot: NP_001394510.1
BRCA1 NM_001407582.1
HGVSc / HGVSpc.5162G>Ap.Arg1721Gln
Exon rankExon 18 of 24
missense
Prot: NP_001394511.1

Ensembl Transcripts

BRCA1 ENST00000357654.9
MANE Select
HGVSc / HGVSpc.5096G>Ap.Arg1699Gln
Exon rankExon 17 of 23
missense
Prot: ENSP00000350283
BRCA1 ENST00000468300.6
TSL:1
HGVSc / HGVSpc.1784G>Ap.Arg595Gln
Exon rankExon 17 of 22
missense
Prot: ENSP00000417148
BRCA1 ENST00000591534.6
TSL:1
HGVSc / HGVSpc.569G>Ap.Arg190Gln
Exon rankExon 5 of 11
missense
Prot: ENSP00000467329

Frequencies

Allele frequencies (AF), counts (AC/AN), homozygotes and coverage

Common (AF > 0.05 / Hom > 5)
Rare (AF ≤ 0.0001 / Hom ≤ 1)
Global population databases 6 sources
GnomAD3 genomes
AF: 0.0000132
AC:2
Hom:0
AN:152020
Cov:32
GnomAD2 exomes
AF: 0.0000239
AC:6
AN:251262
GnomAD4 exome
AF: 0.0000192
AC:28
Hom:0
AN:1461796
Cov:31
GnomAD4 genome
AF: 0.0000132
AC:2
Hom:0
AN:152020
Cov:32
TOPMed (Bravo)
AF: 0.0000227
AC:6
Hom:0
AN:264690
ALFA (dbGaP/dbSNP Allele Frequency Aggregator)
AF: 0.00
AC:0
Hom:0
AN:137886
Local & regional cohorts 2 sources
ChinaMAP Phase 1
AF: 0.0000492
ToMMo 61KJPN (+60KJPN MNV)
AF: 0.000155
AC:19
Hom:0
AN:122562
Showing 8 sources

Case/control cohorts

CohortCasesControls
AFACANAFACAN
ASC
(Autism)
0.000360 *411112 0.000341 *617618
BipEx
(Bipolar disorder (including schizoaffective))
0.00 028420 0.0000693 228844
Epi25
(Epilepsy)
0.0000238 141958 0.0000150 166888
SCHEMA
(Schizophrenia)
0.0000530 6113134 0.0000525 10190576
Showing 4 cohortsAllele count / allele number. *AF is computed from the counts for ASC (not provided by the source).

ClinVar

ClinVar submissions
Significance:Pathogenic
Revision:reviewed by expert panel
View on ClinVar
Pathogenic
VUS
Benign
Condition
17
1
-
Breast-ovarian cancer, familial, susceptibility to, 1 (18)
15
-
-
not provided (15)
9
-
-
Hereditary breast ovarian cancer syndrome (10)
3
-
-
Hereditary cancer-predisposing syndrome (3)
2
-
-
BRCA1-related disorder (2)
1
1
-
Breast and/or ovarian cancer (2)
2
-
-
Familial cancer of breast (2)
1
-
-
BRCA1-related cancer predisposition (1)
1
-
-
Breast-ovarian cancer, familial, susceptibility to, 1;C2936783:Lynch syndrome 1 (1)
1
-
-
Familial cancer of breast;C2676676:Breast-ovarian cancer, familial, susceptibility to, 1;C3280442:Pancreatic cancer, susceptibility to, 4;C4554406:Fanconi anemia, complementation group S (1)
1
-
-
Fanconi anemia, complementation group S (1)
1
-
-
Gastric cancer (1)
1
-
-
Ovarian neoplasm (1)

Computational Scores

AlphaGenome AVI
Pathogenic30
AlphaMissense
Pathogenic0.73
BayesDel_addAF
Pathogenic0.35D
BayesDel_noAF
Pathogenic0.42
CADD
Pathogenic29
DANN
Pathogenic1.0
DEOGEN2
Benign0.39T
Eigen
Pathogenic0.87
Eigen_PC
Pathogenic0.83
FATHMM_MKL
Uncertain0.94D
FuncVEP CTI
Pathogenic0.99
GPN-Star LLR
N/A-7.9
GPN-Star score
N/A7.9
LIST_S2
Pathogenic0.99D
M_CAP
Pathogenic0.75D
MetaRNN
Pathogenic0.84D
MetaSVM
Pathogenic0.94D
Mutation Taster
N/A1/99disease causing (ClinVar)
MutationAssessor
Pathogenic3.2M
PhyloP100
Uncertain4.9
popEVE
Benign-4.2
PrimateAI
Uncertain0.66T
PROVEAN
Uncertain-3.1D
RBP_binding_hub_radar
N/A0.0
RBP_regulation_power_radar
N/A1.7
REVEL
Pathogenic0.79
Sift
Uncertain0.0040D
Sift4G
Uncertain0.058T
Varity_R
N/A0.97
VESM-3B
Benign-11
Showing 30 of 30 scores

Splicing Scores

Pangolin (max)
Uncertain0.23
Pangolin loss
Uncertain0.23
Position offset: 21
SpliceAI score (max)
Benign0.15
Details are displayed if max score is > 0.2
Splicevardb
N/A0.0
Showing 4 of 4 scores

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.

MaveDB functional evidence

MaveDB is a public repository of laboratory assays that test the effect of thousands of variants at once — treat this as supporting research data and interpret it with great caution; it is not a clinical classification.

No MaveDB functional evidence found for this variant.

Publications

Other links and lift over

dbSNP: rs41293459;
hg19: chr17-41215947;
COSMIC: COSV58797961;
COSMIC: COSV58797961;
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.